SCHEMBL45365

SCHEMBL45365

[CH2]C(Cl)C(F)CC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1469598 0.73
SCHEMBL13296092 0.71
SCHEMBL23283075 0.71
SCHEMBL27521620 0.71
SCHEMBL8309034 0.71
SCHEMBL20748947 0.69
SCHEMBL718814 0.68
SCHEMBL477938 0.68
SCHEMBL8074326 0.68
SCHEMBL43759 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2578 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016029146-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON (US) 2016-02-25 WO claimed
US-20240228509-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2024-07-11 US disclosed
WO-2024129931-A1 ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY ALNYLAM PHARMACEUTICALS, INC. (US) 2024-06-20 WO disclosed
US-20240199572-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-06-20 US disclosed
US-20240190872-A1 FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-06-13 US disclosed
EP-4377486-A1 METHOD OF SELECTIVE PRECIPITATION OF METALS USING AMIDE COMPOUNDS The University Court Of The University of Edinburgh (GB) 2024-06-05 EP disclosed
US-11999885-B2 Hydroporphyrin beads with narrow fluorescence emissions NIRVANA SCIENCES INC. (US) 2024-06-04 US disclosed
EP-4373815-A1 SUBSTITUTED HETERO-BICYCLOCOMPOUNDS AS SUBTYPE SELECTIVE NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-05-29 EP disclosed
US-20240166598-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-05-23 US disclosed
EP-4140991-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2024-05-15 EP disclosed
WO-2000058318-A1 PHOSPHATE CONTAINING MACROCYCLIC IMMUNOMODULATORS ABBOTT LABORATORIES (US) 2000-10-05 WO disclosed
US-6124474-A Synthesis of chiral 2-azetidinemethanol compounds ABBOTT LABORATORIES (US) 2000-09-26 US disclosed
US-6121257-A SIDE EFFECT REDUCTION ABBOTT LABORATORIES (US) 2000-09-19 US disclosed
WO-2000051986-A1 CYCLOPENTANONE DIHYDROPYRIDINE COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2000-09-08 WO disclosed
WO-2000044755-A1 DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2000-08-03 WO disclosed
WO-2000024741-A2 DIHYDROPYRIDINE COMPOUNDS AND THEIR USE AS POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2000-05-04 WO disclosed
WO-2000024743-A1 PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE ABBOTT LABORATORIES (US) 2000-05-04 WO disclosed
WO-2000024719-A1 PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS ABBOTT LABORATORIES (US) 2000-05-04 WO disclosed
WO-2000023444-A1 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2000-04-27 WO disclosed
WO-2000007997-A1 IMIDAZOLES AND RELATED COMPOUNDS AS α1A AGONISTS ABBOTT LABORATORIES (US) 2000-02-17 WO disclosed